SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 1, 2004
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-31979 |
|
84-1460811 |
|
(State or Other |
|
(Commission |
|
(IRS Employer |
|
|
|
|
|
|
|
3200 Walnut Street, Boulder, Colorado |
|
|
|
80301 |
|
(Address of Principal Executive Offices) |
|
|
|
(Zip Code) |
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (303) 381-6600 |
||||
|
|
||||
|
|
||||
|
(Former Name or Former Address, if Changed Since Last Report) |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. REGULATION FD
On November 1, 2004, the Registrant and InterMune, Inc. issued a joint press release announcing the extension of a Drug Discovery Program between the two companies, the full text of which is attached hereto as Exhibit 99.1.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
99.1 Press release dated November 1, 2004 entitled “InterMune Announces Presentation of Data on Potent HCV Protease Inhibitor Drug Candidates – Extends Hepatitis C Drug Discovery Program With Array BioPharma.”
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ARRAY BIOPHARMA INC. |
|
|
|
|
|
|
|
|
|
|
Date: November 1, 2004 |
By: |
/s/ Robert E. Conway |
|
|
|
Robert E. Conway |
|
|
|
Chief Executive Officer |
3
EXHIBIT INDEX
|
Exhibit No. |
|
|
|
|
|
|
|
99.1 |
|
Press release dated November 1, 2004 entitled “InterMune Announces Presentation of Data on Potent HCV Protease Inhibitor Drug Candidates – Extends Hepatitis C Drug Discovery Program With Array BioPharma.” |
4